The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure

European Journal of Heart Failure

Volumn 8, Issue 6, 2006, Pages 628-633

  Larsen, A I ^a   Dickstein, K ^a   Ahmadi, N S ^b   Aarsland, T ^c   Kvaloy J T ^d   Hall, C ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c Hjertelaget Research Foundation   (Norway)

^d UNIVERSITY OF STAVANGER   (Norway)

Author keywords

Haemodynamics; Heart failure; Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; GLYCERYL TRINITRATE; NICORANDIL; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INFUSION; FEMALE; HEART FAILURE; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HUMAN; LONGITUDINAL STUDY; LUNG CAPILLARY PRESSURE; MALE; OBSERVATIONAL STUDY; PATIENT CODING; PRESSURE MEASUREMENT; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SYSTEMIC VASCULAR RESISTANCE;

CARDIAC OUTPUT, LOW; CROSS-OVER STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; NICORANDIL; NITROGLYCERIN; PEPTIDE FRAGMENTS; RADIOIMMUNOASSAY; STROKE VOLUME; TIME FACTORS; VASOCONSTRICTION; VASODILATION; VASODILATOR AGENTS;

EID: 33750023221     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2005.11.018     Document Type: Article

References (25)

1. Dickstein K., Larsen A.I., Bonarjee V., Thoresen M., Aarsland T., and Hall C. Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. Am J Cardiol 76 (1995) 679-683
2. Jourdain P., Funck F., Bellorini M., et al. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail 5 (2003) 155-160
3. Richards A.M., Nicholls M.G., Espiner E.A., et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107 (2003) 2786-2792
4. Dickstein K., Aarsland T., and Hall C. Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure. J Card Fail 3 (1997) 83-89
5. Garcia R., Thibault G., Nutt R., Cantin M., and Genest J. Comparative vasoactive effects of native and synthetic atrial natriuretic factor (NAF). Biochem Biophys Res Commun 119 (1984) 685-699
6. Mathisen P., Hall C., and Simonsen S. Comparative study of atrial peptides ANP (1-98) and ANP (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand J Clin Lab Invest 53 (1993) 41-49
7. Downie P.F., Talwar S., Squire I.B., Davies J.E., Barnett D.B., and Ng L.L. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin Sci (Lond) 97 (1999) 255-258
8. Sundsfjord J.A., Thibault G., Larochelle P., and Cantin M. Identification and plasma concentrations of the N-terminal fragment of atrial natriuretic factor in man. J Clin Endocrinol Metab 66 (1988) 605-610
9. Leier C.V., Bambach D., Thompson M.J., Cattaneo S.M., Goldberg R.J., and Unverferth D.V. Central and regional hemodynamic effects of intravenous isosorbide dinitrate, nitroglycerin and nitroprusside in patients with congestive heart failure. Am J Cardiol 48 (1981) 1115-1123
10. Elkayam U., Kulick D., McIntosh N., Roth A., Hsueh W., and Rahimtoola S.H. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 76 (1987) 577-584
11. Larsen A.I., Goransson L., Aarsland T., Tamby J.F., and Dickstein K. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J 134 (1997) 435-441
12. Kamijo T., Kamei K., Sugo I., Kamiyama T., Sudo H., and Ohba Y.J. Hemodynamic and hormonal responses to nicorandil in a canine model of acute ischemic heart failure: a comparison with cromakalim and nitroglycerin. Cardiovasc Pharmacol 33 (1999) 93-101
13. Schulz H., Langvik T.A., Lund Sagen E., Smith J., Ahmadi N., and Hall C. Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma. Scand J Clin Lab Invest 61 (2001) [33 ± 42]
14. Sundsfjord J.A., Thibault G., Larochelle P., and Cantin M. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 66 3 (1988) 605-610
15. Diggle P.J., Heagerty P., Liang K.Y., and Zeger S.L. Analysis of longitudinal data. Second edition (2002), Oxford University Press
16. Keller N., Sykulski R., Thamsborg G., Storm T., and Larsen J. Changes in atrial natriuretic factor during preload reduction with nitroglycerin in patients with congestive heart failure. Clin Physiol 8 (1988) 57-64
17. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 (1994) 195-203
18. Lewis B.S., Makhoul N., Dakak N., et al. Atrial natriuretic peptide in severe heart failure: response to controlled changes in atrial pressures during intravenous nitroglycerin. Am Heart J 124 (1992) 1009-1016
19. Webster M.W., Sharpe D.N., Coxon R., et al. Effect of reducing atrial pressure on atrial natriuretic factor and vasoactive hormones in congestive heart failure secondary to ischemic and nonischemic dilated cardiomyopathy. Am J Cardiol 63 (1989) 217-221
20. Ogawa T., Linz W., Stevenson M., et al. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation 93 (1996) 2059-2067
21. Johnson W., Omland T., Hall C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39 (2002) 1623-1629
22. Yoshimura M., Yasue H., Tanaka H., et al. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J 72 (1994) 528-533
23. Maeda K., Tsutamoto T., Wada A., Hisanaga T., and Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135 (1998) 825-832
24. Smith M.W., Espiner E.A., Yandle T.G., Charles C.J., and Richards A.M. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol 167 (2000) 239-246
25. Yoshimura M., Mizuno Y., Harada E., et al. Interaction on metabolic clearance between A-type and B-type natriuretic peptides in patients with heart failure. Metabolism 49 (2000) 1228-1233